Clinical study of tazobactam/piperacillin in complicated urinary tract infections

For the treatment of urinary tract infections (UTI), a newly developed injectable antibiotic agent, tazobactam/piperacillin (TAZ/PIPC), was administered to 22 UTI cases (complicated: 21, uncomplicated: 1) at a dose of 2.5g/day to 5.0g/day for 5 to 6 days. The results obtained were as follows: 1. Of the 22 cases, 20 cases were evaluable for clinical efficacy by the Japanese UTI criteria. Excellent or good efficacy was obtained in 85%, or 17 out of 20 cases. 2. The clinical isolates obtained before treatment were 11 species of bacteria and 30 strains. After treatment, 26 strains were eradicated. Thus, the eradication rate was 86.7%. 3. Among 27 strains whose β-lactamase production was examined, 15 produced penicillinase and/or cephalosporinase. 4. The drug showed superior antibacterial activity even against β-lactamase producingstrains, as well non-producing strains, especially against Serratia marcescens, in comparison with piperacillin. 5. No subjective or objective adverse reactions were observed in any treated cases. Slight elevation of GPT was observed in two cases and eosinophilia was observed in one case.